Unbound concentration of ertapenem and meropenem in fatty tissue and peritoneal fluid [ Time Frame: within 24 h after administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Number of Adverse Events (total and per patient) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 3 weeks ] [ Designated as safety issue: Yes ]

Number of Serious Adverse Events (total and per patient) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 3 weeks ] [ Designated as safety issue: Yes ]

Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 3 weeks ] [ Designated as safety issue: Yes ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01407965